← All trials
NCT05846347
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2023
- Primary completion
- Oct 19, 2023
- Completion date
- Apr 19, 2025
- First posted
- May 6, 2023
- Last posted
- May 11, 2023
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Gracell Biotechnology Ltd.Collaborator
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityReponsible party - principal investigator
- Zhejiang UniversitySponsor investigator
- Zhejiang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.